Find clinical trials for Pancreatic Cancer in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near Paris, Île-de-France, FRA:
A unique approach for cancer treatment including radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes in ...
Villejuif, France and 7 other locations
Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer...
Phase 2
Villejuif, Villejuif Cedex, France and 135 other locations
assessed by estimating Objective response rate (ORR) according to Response Evaluation Criteria version 1.1 (RECIST 1.1) in patients with pancreatic...
Phase 2
Paris, France and 4 other locations
phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety pr...
Phase 1
Villejuif, France and 76 other locations
Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic du...
Phase 1, Phase 2
Paris, France and 13 other locations
Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC);* PROCEADE PanTumor: A Phase 1b/2, Multicenter, O ...
Phase 1, Phase 2
Paris, France and 48 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
Villejuif, France and 35 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Villejuif, France and 59 other locations
concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors...
Phase 2
Paris, France and 10 other locations
to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors...
Phase 2
Paris, France and 63 other locations
Clinical trials
Research sites
Resources
Legal